What's Happening?
Bruin Biometrics, a UCLA spin-off, has developed a scanning device called ProVizio to detect precursor conditions for pressure ulcers, commonly known as bedsores. This innovation aims to address the significant healthcare burden posed by pressure ulcers, which
cost the industry up to $27 billion annually. The device detects sub-epidermal moisture, allowing caregivers to implement preventive measures before ulcers form. The technology has received FDA approval and is gaining traction in hospitals and nursing facilities, offering a proactive approach to patient care.
Why It's Important?
The development of the ProVizio scanner represents a significant advancement in healthcare technology, potentially reducing the incidence and treatment costs of pressure ulcers. By enabling early detection, the device can improve patient outcomes and reduce the financial burden on healthcare providers. This innovation aligns with broader efforts to enhance patient safety and care quality, highlighting the role of technology in transforming healthcare practices and improving efficiency.
What's Next?
Bruin Biometrics plans to expand the use of its ProVizio device beyond pressure ulcer detection to include patients with diabetes and circulatory issues. The company is also working to increase market penetration and secure reimbursement from Medicare and Medicaid for the device's use. As the technology gains wider adoption, it could set a new standard for preventive care in healthcare settings.
